Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Quaker BioVentures is a venture capital firm investing in life science companies. The firm leads investments across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals, and healthcare services. Quaker BioVentures invests in companies at all stages of development, from early stage start-ups to public companies. Founded in 2003, the firm is currently investing Quaker BioVentures II, a $420 million fund formed in 2007. Quaker BioVentures manages over $700 million in committed capital.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
6/2007 | Argolyn Bioscience | Series A | 15.8M |
3/2006 | Nitric Bio | Series A | 14M |
3/2006 | Helomics | Venture Round | 20M |
3/2007 | Regado Biosciences | Series C | 23M |
4/2013 | RainDance Technologies | Series E | 0 |
12/2002 | BioRexis | Series A | 8M |
8/2009 | Rapid Micro Biosystems | Series A | 18.6M |
11/2008 | Tengion | Series C | 0 |
4/2004 | MedMark Treatment Centers | Venture Round | 28M |
6/2010 | Helomics | Series D | 33M |
1/2010 | Tarsa Therapeutics | Series A | 24M |
6/2006 | TetraLogic Pharmaceuticals | Series B | 36M |
6/2011 | NovaSom | Series D | 35M |
3/2004 | BioRexis | Series B | 30M |
2/2005 | Neotropix | Series A | 10M |
7/2008 | Celator Pharmaceuticals | Series C | 22.5M |
3/2008 | EKR Therapeutics | Series D | 50M |
9/2013 | PreCision Dermatology | Debt Financing | 67M |
8/2007 | Celator Pharmaceuticals | Series C | 10M |
4/2005 | TargetRx | Series D | 0 |
10/2007 | Tengion | Series C | 33M |
6/2006 | Tengion | Series B | 50M |
1/2010 | BioLeap | Series A | 5M |
9/2010 | Celator Pharmaceuticals | Series D | 0 |
5/2010 | TearScience | Series C | 44.5M |
6/2004 | Nucleonics | Series B | 49.2M |
6/2009 | Cempra | Series C | 46M |
9/2005 | Amicus Therapeutics | Series C | 55M |
8/2010 | TetraLogic Pharmaceuticals | Series C | 0 |
5/2011 | Neuronetics | Series E | 30M |
10/2009 | Asensus Surgical | Post-IPO Equity | 0 |
4/2015 | Neuronetics | Series F | 0 |
9/2005 | Biolex Therapeutics | Series B | 36M |
5/2007 | Biolex Therapeutics | Series C | 30M |
9/2006 | Amicus Therapeutics | Series D | 60M |
6/2010 | Corridor Pharmaceuticals | Series A | 0 |
3/2012 | Tarsa Therapeutics | Series B | 28M |
4/2008 | Transave | Series D | 35M |
3/2019 | Kaarta | Series A | 0 |
5/2005 | Tranzyme | Series A | - |
11/2008 | Helomics | Venture Round | 43M |
7/2008 | NuPathe | Series B | 30M |
4/2008 | Diasome Pharmaceuticals | Series B | 8.4M |
4/2007 | StageMark | Series B | 1.6M |
8/2007 | EKR Therapeutics | Series C | 13M |
8/2010 | Achillion Pharmaceuticals | Post-IPO Equity | 50.1M |
10/2007 | Optherion | Series A | 37M |
1/2011 | RainDance Technologies | Series D | 37.5M |
10/2009 | Sleep Solutions | Series F | 20M |
10/2008 | Biolex Therapeutics | Series D | 0 |
11/2007 | Tranzyme | Venture Round | 20M |
12/2009 | Regado Biosciences | Series D | 0 |
9/2012 | Intact Vascular | Series A | 15.5M |
8/2003 | Biolex Therapeutics | Venture Round | 0 |
5/2005 | Celator Pharmaceuticals | Series B | 20M |
10/2009 | Neuronetics | Series D | 0 |
10/2008 | Corridor Pharmaceuticals | Seed Round | 0 |
3/2019 | Kaarta | Series A | 0 |
4/2015 | Neuronetics | Series F | 0 |
9/2013 | PreCision Dermatology | Debt Financing | 0 |
4/2013 | RainDance Technologies | Series E | 0 |
9/2012 | Intact Vascular | Series A | 0 |
3/2012 | Tarsa Therapeutics | Series B | 0 |
6/2011 | NovaSom | Series D | 0 |
5/2011 | Neuronetics | Series E | 0 |
1/2011 | RainDance Technologies | Series D | 0 |
1/2011 | TetraLogic Pharmaceuticals | Series C | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|